Gunderson Dettmer represented Colossal Biosciences on the deal.Colossal Biosciences, a genetic engineering company, announced its $150 million Series B financing led by United States Innovative Technology Fund….
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
